Brevan Howard Capital Management LP Sells 12,453 Shares of Henry Schein, Inc. $HSIC

Brevan Howard Capital Management LP lowered its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 22.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,224 shares of the company’s stock after selling 12,453 shares during the period. Brevan Howard Capital Management LP’s holdings in Henry Schein were worth $2,869,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC bought a new position in shares of Henry Schein during the 2nd quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new stake in Henry Schein during the 2nd quarter valued at $27,000. Sentry Investment Management LLC lifted its position in Henry Schein by 132.1% in the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock worth $59,000 after buying an additional 515 shares during the last quarter. Evelyn Partners Investment Management Services Ltd purchased a new position in Henry Schein during the second quarter worth $62,000. Finally, Mather Group LLC. purchased a new position in Henry Schein during the third quarter worth $71,000. 96.62% of the stock is owned by institutional investors.

Henry Schein Stock Down 1.3%

NASDAQ:HSIC opened at $74.61 on Tuesday. The company has a market cap of $8.56 billion, a price-to-earnings ratio of 22.82, a price-to-earnings-growth ratio of 2.24 and a beta of 0.87. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $89.29. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59. The stock has a fifty day simple moving average of $78.13 and a 200-day simple moving average of $72.93.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. The firm had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HSIC. Wells Fargo & Company increased their target price on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Robert W. Baird set a $100.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Monday, February 23rd. Wall Street Zen downgraded shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Saturday. UBS Group increased their price objective on shares of Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Finally, Barrington Research set a $97.00 target price on Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $85.58.

Insider Activity at Henry Schein

In other Henry Schein news, EVP Mark E. Mlotek sold 5,925 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total value of $478,740.00. Following the transaction, the executive vice president directly owned 80,554 shares in the company, valued at $6,508,763.20. This represents a 6.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Philip A. Laskawy sold 2,844 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the transaction, the director directly owned 21,961 shares in the company, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 104,556 shares of company stock valued at $8,476,351 over the last 90 days. 1.14% of the stock is currently owned by insiders.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.